National telehealth GLP-1 companies win on convenience, not relationships. Local practices compete with telehealth GLP-1 companies by owning positioning, referrals, and the in-person patient relationship an app can’t replicate.
A new clinical trial gives providers objective, measured evidence on DAO Botox® injection technique and its effect on lower-face muscle balance. The findings show why new injectors need to think beyond the patient’s stated concern to guide both the treatment and the result.
Building patient trust in aesthetic medicine happens in minutes, not years — and it’s just as fragile. Here’s how new providers earn it fast, and the missteps that break it just as quickly.
Many physicians leave employed medicine only to rebuild the same hours-for-dollars trap in a nicer room. The difference comes down to your aesthetic practice business model: an asset that pays you while you sleep, or a job you can never leave.
June’s clinical evidence points to a more disciplined approach to combination care: select and sequence treatment based on anatomy, evidence quality, recovery burden, and the patient’s changing trajectory. This update examines new data on skin-quality injectables, radiofrequency microneedling, and regenerative approaches to help aesthetic providers build safer, more individualized plans.
June 2026 delivered a wave of new clinical data and regulatory updates that clarify the path forward for medical weight management. From the ACP’s new prescribing hierarchy to the launch of the Medicare GLP-1 Bridge and the rising potency of multi-agonists, the need for structured, physician-led care has never been more urgent.
The “Wolverine Stack” pairs BPC-157 and TB-500 on the promise of faster tissue repair, but the combination has never been tested in a human clinical trial. This review covers what the evidence and regulatory record actually show, so providers can answer patient questions with confidence.
The June 2026 FDA approval of SKINVIVE by JUVÉDERM for horizontal neck lines gives aesthetic providers a new on-label option for an area that has historically relied on off-label approaches. Understanding where it fits — and where it doesn’t — is what separates confident treatment planning from guesswork.
The most qualified patient who walks into an aesthetic practice is usually one sent by another provider — someone who already trusts the recommendation before they call to book. Building those relationships requires deliberate outreach, not just doing good work and waiting.
Hair shedding is one of the most commonly reported but least-addressed sequelae of GLP-1-related weight loss, and it often overlaps with menopausal female pattern hair loss in the same patient. Aesthetic providers who can identify both presentations and offer structured interventions have a meaningful clinical and practice expansion opportunity.